Neogen Chemicals · NSE: NEOGEN · BSE: 542665

Q4 FY25 results · Jan–Mar 2025

Neogen Chemicals reported revenue from operations of ₹202.82 crore (up 1.6% from Q4 FY24) and net profit of ₹2.41 crore (down 85.8% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.

Consolidated · ₹ crore
ItemQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue from operations202.82199.65+1.6%201.43+0.7%
Other income0.592.21−73.3%1.06−44.3%
Total income203.41201.86+0.8%202.49+0.5%
Profit before share of associates & JVs and tax3.6322.45−83.8%15.17−76.1%
Share of profit/(loss) of associates & JVs0.050.020.08
Net profit for the period2.4116.93−85.8%10.01−75.9%
EPS, basic (₹)0.916.42−85.8%3.80−76.1%
Net margin (%)1.28.55.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue from operations203.75190.63+6.9%200.41+1.7%
Other income2.653.59−26.2%2.05+29.3%
Total income206.40194.22+6.3%202.46+1.9%
Profit before tax7.7523.23−66.6%20.05−61.3%
Net profit for the period5.1917.70−70.7%14.41−64.0%
EPS, basic (₹)1.976.71−70.6%5.46−63.9%
Net margin (%)2.59.37.2
Consolidated
Filed with BSE
17 May 2025, 22:57 IST
Board meeting
17 May 2025
Period
01 Jan 2025 to 31 Mar 2025
Review status
Audited
Source
XBRL filing on BSE
Standalone
Filed with BSE
17 May 2025, 22:57 IST
Board meeting
17 May 2025
Period
01 Jan 2025 to 31 Mar 2025
Review status
Audited
Source
XBRL filing on BSE